Roche moved to shut down its Huntington’s disease development programs, ending clinical work on tominersen after a Phase 2 failure and stopping a separate early-stage asset following preclinical safety findings. The decision, communicated in a letter to the patient community, underscores how little progress remains for antisense approaches after repeated efficacy setbacks. Roche said tominersen met safety and biomarker endpoints but did not deliver an efficacy improvement in disease severity over a 16-month treatment period. For RG6496, Roche cited an animal result indicating the candidate could not be administered chronically with repeated dosing, leading to discontinuation before broader human testing. Roche added that its gene therapy program RG6662 remains ongoing as planned, positioning the company to continue focusing on alternative modalities while closing the door on two ASO development paths.